GlassScriptPhysician profile
Robert Nicholas Pica
NPI 1497001747
$75,703.96
in general payments reported to CMS, 2019-2025
28 companies · $54K in 2025
The $54K reported for 2025 was more than what 99% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.79 · 2020: $1,706 · 2021: $35.96 · 2022: $123 · 2023: $408 · 2024: $19K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Travel and Lodging: $11K · Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,700.00 |
| Travel and Lodging | $11,009.37 |
| Food and Beverage | $3,098.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $72,147.15 | 2020-2025 | |
| Stryker Corporation | $1,143.75 | 2024 | Prostep, Prostep Mica |
| Fortis Surgical, LLC | $950.72 | 2020-2023 | |
| Organogenesis INC. | $320.79 | 2019-2025 | Affinity, Simplimax, Via Matrix |
| Smith+Nephew, INC. | $231.15 | 2022-2025 | Grafix, Stravix, Renasys Go V2 Home |
| Vertex Pharmaceuticals Incorporated | $90.12 | 2024-2025 | |
| Globus Medical, INC. | $86.12 | 2025 | Senza |
| Biocomposites INC | $85.68 | 2023-2024 | Stimulan |
| Anika Therapeutics, INC. | $71.82 | 2024 | Integrity, Toe Motion |
| Ani Pharmaceuticals, INC. | $56.66 | 2024-2025 | Purified Cortrophin Gel |
| Bioventus LLC | $53.10 | 2021-2025 | Exogen Ultrasound Bone Healing System |
| Boston Scientific Corporation | $52.66 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Convatec INC. | $48.34 | 2023-2024 | |
| Abbott Laboratories | $45.15 | 2023 | Proclaim |
| Abbvie INC. | $44.99 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $44.79 | 2025 | Arista |
| Ibsa Pharma INC. | $43.61 | 2023 | Tirosint, Licart |
| Lifenet Health | $31.53 | 2025 | Theragenesis Wound Matrix |
| Medtronic, INC. | $24.35 | 2023 | Venaseal |
| Next Science LLC | $23.08 | 2023 | Blastx, Xperience, Surgx |
| Sanara Medtech INC. | $20.08 | 2025 | Celleraterx |
| Averitas Pharma INC. | $19.08 | 2023 | Qutenza |
| Kerecis Limited | $18.82 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Sebela Pharmaceuticals INC. | $15.71 | 2020 | |
| Tactile Systems Technology INC | $15.05 | 2021 | |
| Mimedx Group, INC. | $13.47 | 2024 | |
| Heron Therapeutics, INC. | $6.19 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$62,506.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.